Pure Global AI
NCT06026995Recruiting

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Clinical Study on the Effectiveness and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells for Lymphoma and Multiple Myeloma
Chongqing University Cancer HospitalPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
PEG-rhG-CSF
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chongqing University Cancer Hospital
Location
Chongqing, China
Timeline & enrollment
Phase
Phase 4
Start date
Mar 01, 2022
End date
Jun 01, 2024
Enrollment
174 participants
Primary outcome

The proportion of patients with CD34+ cells ≥2×106/kg

Summary

This study is a randomized controlled, open and multi-center clinical study. Patients who
 meet the selection criteria and do not meet the exclusion criteria are randomly given
 PEG-rhG-CSF with a fixed dose of 12mg when white blood cells reach the lowest point, or given
 rhG-CSF with a daily mobilization of 5-10μ g/kg until the collection is completed, so as to
 evaluate the effectiveness and safety of PEG-rhG-CSF in mobilizing autologous stem cells for
 lymphoma and multiple myeloma.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06026995
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06026995 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chongqing University Cancer Hospital and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 174 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.